Additional findings from the CodeBreak 200 trial
OHC – Oncology Hematology Care shared a post on LinkedIn:
“OHC medical oncologist and hematologist David Waterhouse, MD, MPH, recently published additional findings from the revolutionary CodeBreak 200 trial that led to the FDA approval of sotorasib for the treatment of non-small cell lung cancer for patients with the KRAS gene mutation.
Dr. Waterhouse states, ‘Sotorasib was the first agent to successfully target KRAS. This target has been very difficult to address despite the fact that we have known about it for nearly 40 years. The approval was based on the improved progression-free survival and patient-reported outcomes (PROs).’
The PROs were a contributing factor to the FDA’s approval, and this new paper explains in detail the PROs from the study and why they are important to consider for new therapies.
Read more here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023